JP2002145791A - Anti-inflammatory composition - Google Patents
Anti-inflammatory compositionInfo
- Publication number
- JP2002145791A JP2002145791A JP2000340152A JP2000340152A JP2002145791A JP 2002145791 A JP2002145791 A JP 2002145791A JP 2000340152 A JP2000340152 A JP 2000340152A JP 2000340152 A JP2000340152 A JP 2000340152A JP 2002145791 A JP2002145791 A JP 2002145791A
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- inflammatory composition
- ginseng
- composition
- glue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、抗炎症性組成物に
関し、更に詳細には、複数の生薬成分および膠飴を含有
し、胃や腸等の消化器系器官での炎症症状を治療ないし
緩和することのできる抗炎症性組成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an anti-inflammatory composition, and more particularly, to an anti-inflammatory composition containing a plurality of crude drug components and glue, for treating inflammatory conditions in digestive organs such as the stomach and intestines. It relates to an anti-inflammatory composition that can be alleviated.
【０００２】[0002]
【従来の技術】消化器系器官での炎症は、生体組織が有
害な刺激を受けた場合に、これに続いてその局所に惹起
される一連の組織反応、防衛反応とされている。この炎
症の原因としては、機械的、物理的、化学的、生化学的
刺激等が挙げられるが、その他に、腸内細菌のバランス
が重要な因子となると考えられている。2. Description of the Related Art Inflammation in the digestive organs is considered to be a series of tissue reactions and defense reactions which are locally induced when a living tissue receives a harmful stimulus. Causes of this inflammation include mechanical, physical, chemical, biochemical stimuli, etc. In addition, the balance of intestinal bacteria is considered to be an important factor.
【０００３】現在、このような炎症の治療には、アセチ
ルサリチル酸類をはじめとする化学合成された抗炎症剤
や抗生物質の投与等も行われている。[0003] At present, the treatment of such inflammation includes administration of chemically synthesized anti-inflammatory agents such as acetylsalicylic acids and antibiotics.
【０００４】しかしながら、上記の方法は、特に消化器
系器官で生じる炎症、例えば、大腸炎や食物アレルギー
に伴う炎症等においては適当でない場合も多い。すなわ
ち、化学合成された抗炎症剤は、胃や腸内組織に障害を
与えることがある。また、腸内には多くの腸内細菌が生
息しており、消化作用の一端を担っているが、抗生物質
の投与などを行えば一時的にこれらの腸内微生物が死滅
し、下痢等の原因となる場合があるなどの問題もあっ
た。[0004] However, the above method is often unsuitable especially for inflammation occurring in digestive organs, for example, inflammation associated with colitis or food allergy. That is, the chemically synthesized anti-inflammatory agent may damage the stomach and intestinal tissues. In addition, many intestinal bacteria inhabit the intestine and play a part in the digestive action.However, administration of antibiotics etc. temporarily kills these intestinal microorganisms and causes diarrhea. There were also problems such as the cause.
【０００５】[0005]
【発明が解決しようとする課題】従って、経口投与した
場合であっても、消化器系器官の組織に影響を与えず、
炎症を治療ないし緩和することのできる医薬の提供が求
められていた。Therefore, even when administered orally, it does not affect the tissues of the digestive organs,
There has been a demand for a drug capable of treating or alleviating inflammation.
【０００６】[0006]
【課題を解決するための手段】本発明者らは、上記課題
を解決すべく鋭意研究を重ねた結果、特定の生薬を組み
合わせることにより得られる抗炎症組成物は、消化器系
器官内に生じる炎症に対して有効であり、しかも消化器
官自体や、腸内微生物等にほとんど悪影響を与えないこ
とを見出し、本発明を完成した。Means for Solving the Problems The present inventors have made intensive studies to solve the above-mentioned problems, and as a result, an anti-inflammatory composition obtained by combining a specific crude drug is produced in digestive organs. The present inventors have found that they are effective against inflammation and have little adverse effect on digestive organs themselves, intestinal microorganisms, and the like, and thus completed the present invention.
【０００７】すなわち本発明は、山椒、乾姜、人参およ
び膠飴を含有する抗炎症性組成物を提供するものであ
る。That is, the present invention provides an anti-inflammatory composition containing Japanese pepper, ginger, ginseng and glue.
【０００８】また本発明は、炎症性疾患患者に対し、上
記抗炎症性組成物を経口投与または経腸投与する炎症症
状の治療、緩和方法を提供するものである。[0008] The present invention also provides a method for treating or alleviating an inflammatory condition in which the above-mentioned anti-inflammatory composition is orally or enterally administered to an inflammatory disease patient.
【０００９】[0009]
【発明の実施の形態】本発明の抗炎症性組成物におい
て、山椒、乾姜、人参および膠飴が有効成分として配合
される。BEST MODE FOR CARRYING OUT THE INVENTION In the anti-inflammatory composition of the present invention, pepper, ginger, ginseng and glue are mixed as active ingredients.
【００１０】これらの成分のうち、山椒、乾姜、人参お
よび膠飴は、いずれも漢方薬成分として公知なものであ
り、例えば市販されている製品をそのまま使用すること
もできる。Among these components, Japanese pepper, dried ginger, ginseng and glue are all known as Chinese herbal components, and for example, commercially available products can be used as they are.
【００１１】本発明の抗炎症性組成物の調製は、上記の
山椒、乾姜および人参（以下、「生薬成分」という）を
細断または粉砕した後、均一に混合したもの、あるいは
更に必要により適当な溶媒により抽出して得たエキス
に、膠飴を混合することにより行われる。また、別の方
法としては、個別に細断または粉砕した生薬成分を抽出
してエキスを得、このエキスに膠飴を加える方法を挙げ
ることができる。The preparation of the anti-inflammatory composition of the present invention may be performed by chopping or pulverizing the above-mentioned pepper, dried ginger and ginseng (hereinafter referred to as "herbal component") and then mixing them uniformly, or if necessary. It is carried out by mixing the extract obtained by extraction with a suitable solvent with glue. Further, as another method, there can be mentioned a method of extracting an individually cut or crushed crude drug component to obtain an extract, and adding glue to this extract.
【００１２】本発明の抗炎症性組成物における、上記各
成分の配合割合は、山椒、乾姜、人参および膠飴を、そ
れらの比で、０．５〜２０：１〜２０：１〜２０：１〜
４００程度とすることが好ましい。また、これら生薬成
分の、組成物全体に対する配合割合は、１０から１００
質量％であることが好ましい。さらに好ましくは、それ
らの比で、０．５〜１０：１〜２０：１〜１５：１〜４
００程度である。これらの生薬成分の組成物全体に対す
る配合割合は、２０から９０質量％であることがさらに
好ましい。[0012] In the anti-inflammatory composition of the present invention, the mixing ratio of each of the above-mentioned components is as follows. : 1
It is preferable to be about 400. Further, the mixing ratio of these crude drug components to the whole composition is 10 to 100.
It is preferable that the content is mass%. More preferably, in those ratios, 0.5 to 10: 1 to 20: 1 to 15: 1 to 4
It is about 00. It is further preferable that the mixing ratio of these crude drug components to the entire composition is 20 to 90% by mass.
【００１３】更に、本発明の抗炎症性組成物には、必要
に応じて、他の成分、例えば薬効成分、矯味成分、賦形
剤、着色剤、抗酸化剤等の医薬用担体や、その他の製剤
上使用しうる成分を適宜配合することもできる。Further, the anti-inflammatory composition of the present invention may contain other components, if necessary, such as a pharmaceutical carrier such as a medicinal component, a flavoring component, an excipient, a coloring agent, an antioxidant, etc. Ingredients that can be used in the preparation can be appropriately blended.
【００１４】なお、本発明においては、上記に代え、山
椒、乾姜、人参および膠飴を含有する漢方薬を使用する
ことも可能である。In the present invention, instead of the above, it is also possible to use a Chinese herb containing Sansho, Ginger, Ginseng and Gum Cane.
【００１５】上記のようにして得られた抗炎症性組成物
は、種々の炎症症状を呈する患者に経口投与することが
できるが、消化器系器官の炎症、例えば、大腸炎、下
痢、腹痛等の患者に投与することが特に有効であり、こ
れら消化器系器官の炎症に伴う、下部消化管不定愁訴等
の症状を治療ないしは緩和させることができる。[0015] The anti-inflammatory composition obtained as described above can be orally administered to patients exhibiting various inflammatory conditions. Is particularly effective, and can treat or alleviate symptoms such as lower gastrointestinal indefinite complaints accompanying inflammation of these digestive organs.
【００１６】本発明の抗炎症性組成物の投与量は、その
炎症の種類、程度や、投与される患者の状態によって相
違するが、例えば、大人一人当たり、山椒、乾姜および
人参のエキス成分と膠飴の合計量として、一日当たり
０.１から５ｇ程度とすれば良い。The dose of the anti-inflammatory composition of the present invention varies depending on the type and degree of inflammation and the condition of the patient to be administered. For example, per adult, an extract component of pepper, ginger and ginseng And the total amount of glue can be about 0.1 to 5 g per day.
【００１７】[0017]
【実施例】以下、実施例および試験例を挙げ、本発明を
更に詳しく説明するが、本発明はこれら実施例等に何ら
制約されるものではない。The present invention will be described in more detail with reference to the following examples and test examples, but the present invention is not limited to these examples.
【００１８】実 施 例 １ 抗炎症性組成物（１） 山椒２.０ｇ、乾姜５.０ｇおよび人参３.０ｇに、処方
生薬総重量の６８倍量の精製水を加え、１００℃で６０
分間程度抽出し、固液分離した。得られた分離液を２分
の１量になるまで濃縮し、濃縮液をスプレードライして
混合生薬エキスを得た。この生薬エキス１.２５ｇに膠
飴１０ｇを混合し、抗炎症性組成物を得た。EXAMPLES Example 1 Anti-inflammatory composition (1) To 2.0 g of sansho, 5.0 g of ginger and 3.0 g of ginseng, 68 times the amount of the total weight of the prescribed crude drug was added to purified water, and the mixture was treated at 60 ° C.
Extracted for about a minute and separated into solid and liquid. The obtained separated solution was concentrated to a half volume, and the concentrated solution was spray-dried to obtain a mixed crude drug extract. 1.25 g of this crude drug extract was mixed with 10 g of glue to obtain an anti-inflammatory composition.
【００１９】実 施 例 ２ 抗炎症性組成物（２） 下記量の生薬を用いる以外は、実施例１と同様にして混
合生薬エキスを得た。この生薬エキス５ｇに膠飴４０ｇ
を混合して抗炎症性組成物を得た。Example 2 Anti-inflammatory composition (2) A mixed crude drug extract was obtained in the same manner as in Example 1 except that the following amount of crude drug was used. 5 g of this crude drug extract and 40 g of glue cane
Was mixed to obtain an anti-inflammatory composition.
【００２０】 [0020]
【００２１】試 験 例 １ 抗 炎 症 試 験 ：６週齢のＳＤ系ラット（雄）を用
い、実施例１で得られた抗炎症性組成物の作用を調べ
た。試験は、一群６匹の上記ラットを２４時間絶食させ
た後、エーテル麻酔下開腹し、大腸上部より５％酢酸水
溶液２ｍｌを注入した。この後、閉腹し、下記投与量の
被験化合物を経口投与した。経口投与２４時間後に再度
開腹し、大腸を取り出して粘膜層と筋層に分けて試料と
し、これらに含まれるミエローパオキシダーゼ（炎症の
初期の段階で産生される酵素；ＭＰＯ）量と、プロスタ
グランジン（ＰＧ）量を測定した。なお、比較品として
は、一般的な抗炎症剤であるインドメタシンおよび潰瘍
性大腸炎に用いられるスルファサラジンを用いた。ま
た、コントロール群としては、５％酢酸水溶液のみを投
与したもの（対照１）および水を投与したもの（対照
２）を用いた。この結果を表１に示す。Test Example 1 Anti-inflammatory disease test: The action of the anti-inflammatory composition obtained in Example 1 was examined using 6-week-old SD rats (male). In the test, a group of 6 rats was fasted for 24 hours, and then abdominal laparotomy was performed under ether anesthesia. Thereafter, the abdomen was closed, and the test compound was orally administered at the following dose. Twenty-four hours after oral administration, the abdomen was reopened, the large intestine was taken out, divided into a mucosal layer and a muscular layer to prepare a sample, and the myelopa oxidase (enzyme produced at an early stage of inflammation; MPO) contained in these samples, The amount of gin (PG) was measured. In addition, as a comparative product, indomethacin which is a general anti-inflammatory agent and sulfasalazine used for ulcerative colitis were used. As control groups, those to which only a 5% acetic acid aqueous solution was administered (Control 1) and those to which water was administered (Control 2) were used. Table 1 shows the results.
【００２２】＜ 被検化合物投与量 ＞ 抗炎症性組成物１ ３００ｍｇ／ｋｇ インドメタシン ２.２ｍｇ／ｋｇ スルファサラジン ４００ｍｇ／ｋｇ<Test Compound Dose> Anti-inflammatory composition 1 300 mg / kg Indomethacin 2.2 mg / kg Sulfasalazine 400 mg / kg
【００２３】（ 結 果 ）(Result)
【表１】 [Table 1]
【００２４】実 験 例 ２ 組織学的解析：試験例１で用いた動物の大腸を、縦方向
に半分に切り、ＰＧ、ＭＰＯを測定した残りを組織学的
解析に供した。この採取した組織を、１５％リン酸緩衝
ホルマリン溶液で固定後、パラフィンで包埋した。これ
をアザン染色および抗シクロオキシゲナーゼ−２（ＣＯ
Ｘ−２）抗体（バイオメダ社）を用いた免疫組織学的検
索を行い、光学顕微鏡で観察した。EXPERIMENTAL EXAMPLE 2 Histological Analysis: The large intestine of the animal used in Experimental Example 1 was cut in half in the longitudinal direction, and the remaining PG and MPO were measured and subjected to histological analysis. The collected tissue was fixed with a 15% phosphate buffered formalin solution, and then embedded in paraffin. This was subjected to Azan staining and anti-cyclooxygenase-2 (CO
X-2) An immunohistological search using an antibody (Biomeda) was performed and observed with an optical microscope.
【００２５】免疫組織学的検索は、抗ＣＯＸ−２抗体に
よりＣＯＸ−２の発現部位を検索し、陽性細胞の出現程
度をグレード分けし（−：変化なし、＋：わずかの増加
あり、＋＋：やや増加あり、＋＋＋：増加あり、＋＋＋
＋：著しく増加あり）、評価した。この結果を表３に示
す。In the immunohistological search, the expression site of COX-2 was searched using an anti-COX-2 antibody, and the appearance of positive cells was graded (-: no change, +: slight increase, ++: There is a slight increase, +++: There is an increase, +++
+: Markedly increased) and evaluated. Table 3 shows the results.
【００２６】[0026]
【表２】 [Table 2]
【００２７】[0027]
【表３】 [Table 3]
【００２８】実験例１および実験例２の結果から、本発
明の抗炎症性組成物は、筋層においてＭＰＯの活性を押
さえたので、炎症を初期の段階で抑制すると共に、腸管
の透過性の亢進を抑制し、バクテリアのトランスロケー
ション等も抑制する可能性が考えられる。また、プロス
タグランジン量は、やや値を下げる程度であったもの
の、組織学的な解析の結果から、ＣＯＸ−２の発現を抑
制していることから、消化管に対して副作用の低い抗炎
症剤になりうるものと判断される。From the results of Experimental Examples 1 and 2, the anti-inflammatory composition of the present invention suppressed the activity of MPO in the muscular layer, so that inflammation was suppressed at an early stage and the intestinal permeability was reduced. It is conceivable that the increase is suppressed and the translocation of bacteria is also suppressed. Although the amount of prostaglandin was slightly reduced, histological analysis showed that the expression of COX-2 was suppressed. It is determined that it can be an agent.
【００２９】[0029]
【発明の効果】本発明の抗炎症性組成物は、炎症、特に
消化器系器官での炎症を有効に抑制する作用を有し、し
かも消化器官自体や、腸内微生物等にほとんど悪影響を
与えないものである。Industrial Applicability The anti-inflammatory composition of the present invention has an effect of effectively suppressing inflammation, particularly inflammation in digestive organs, and has almost no adverse effect on digestive organs themselves and intestinal microorganisms. Not something.
【００３０】また、化学合成された抗炎症剤のように、
経口投与による副作用も認められず、安全なものであ
る。Also, like chemically synthesized anti-inflammatory drugs,
The drug is safe without any side effects due to oral administration.
【００３１】従って、本発明の抗炎症性組成物は、大腸
や小腸等の消化器系器官で生じる種々の炎症、例えば、
大腸炎や食物アレルギーに伴う炎症等の症状を治療ない
しは緩和させることができる抗炎症剤として有利に使用
することができるものである。 以 上Accordingly, the anti-inflammatory composition of the present invention can be used for various inflammations occurring in digestive organs such as the large and small intestines, for example,
It can be advantageously used as an anti-inflammatory agent capable of treating or alleviating symptoms such as colitis and inflammation associated with food allergy. that's all
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｐ 29/00 Ａ６１Ｐ 29/00 (72)発明者 三浦 尚子 茨城県稲敷郡阿見町吉原3586 株式会社ツ ムラ内 (72)発明者 飯塚 生一 茨城県稲敷郡阿見町吉原3586 株式会社ツ ムラ内 Ｆターム(参考） 4C087 AA01 AA02 BB46 CA06 MA02 MA52 MA60 NA14 ZA66 ZB11 4C088 AB18 AB62 AB81 AC04 AC11 AD13 BA07 BA08 CA03 MA07 MA52 MA60 NA14 ZA66 ZB11──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61P 29/00 A61P 29/00 (72) Inventor Naoko Miura 3586 Yoshiwara, Ami-cho, Inashiki-gun, Ibaraki Pref. (72) Inventor Ikuzuka Iiizuka 3586 Yoshiwara, Ami-cho, Inashiki-gun, Ibaraki Pref.T-mura Co., Ltd. MA60 NA14 ZA66 ZB11
Claims (7)
抗炎症性組成物。1. An anti-inflammatory composition comprising pepper, ginger, ginseng and glue.
の比で、０．５〜２０：１〜２０：１〜２０：１〜４０
０で含み、かつこれらが組成物全体の組成の１０から１
００質量％である請求項第１項記載の抗炎症性組成物。2. Pepper, dried ginger, ginseng and glue in a ratio of 0.5 to 20: 1 to 20: 1 to 20: 1 to 40.
0 and these are 10 to 1 of the composition of the overall composition.
The anti-inflammatory composition according to claim 1, wherein the amount is 00% by mass.
するものである請求項第１項または第２項記載の抗炎症
性組成物。3. The anti-inflammatory composition according to claim 1, which is for treating or alleviating inflammatory symptoms in digestive organs.
記載の抗炎症性組成物。4. The anti-inflammatory composition according to claim 3, wherein the digestive organ is a large intestine.
炎症である請求項第３項記載の抗炎症性組成物。5. The anti-inflammatory composition according to claim 3, wherein the inflammation is inflammation associated with colitis or food allergy.
参および膠飴を含有する抗炎症性組成物を経口投与また
は経腸投与することを特徴とする炎症症状の治療、緩和
方法。6. A method for treating or alleviating inflammatory symptoms, which comprises administering orally or enterally an anti-inflammatory composition containing sansho, ginger, ginseng and glue to a patient with an inflammatory disease.
疾患である請求項第６項記載の炎症症状の治療、緩和方
法。7. The method for treating or alleviating an inflammatory condition according to claim 6, wherein the inflammatory disease is an inflammatory disease in a digestive organ.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000340152A JP2002145791A (en) | 2000-11-08 | 2000-11-08 | Anti-inflammatory composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000340152A JP2002145791A (en) | 2000-11-08 | 2000-11-08 | Anti-inflammatory composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002145791A true JP2002145791A (en) | 2002-05-22 |
Family
ID=18815112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000340152A Pending JP2002145791A (en) | 2000-11-08 | 2000-11-08 | Anti-inflammatory composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002145791A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007291008A (en) * | 2006-04-25 | 2007-11-08 | Kowa Co | Gut mucosa protective agent |
| WO2009104248A1 (en) * | 2008-02-19 | 2009-08-27 | 国立大学法人旭川医科大学 | Adrenomedullin production enhancer |
| KR101363311B1 (en) * | 2012-02-01 | 2014-02-17 | 공주대학교 산학협력단 | Zanthoxylum schinifolium extract for prevention and treatment of ulcerative colitis the composition comprising the same |
-
2000
- 2000-11-08 JP JP2000340152A patent/JP2002145791A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007291008A (en) * | 2006-04-25 | 2007-11-08 | Kowa Co | Gut mucosa protective agent |
| WO2009104248A1 (en) * | 2008-02-19 | 2009-08-27 | 国立大学法人旭川医科大学 | Adrenomedullin production enhancer |
| JP5451403B2 (en) * | 2008-02-19 | 2014-03-26 | 国立大学法人旭川医科大学 | Adrenomedullin production enhancer |
| US9193756B2 (en) | 2008-02-19 | 2015-11-24 | National University Corporation Asahikawa Medical College | Adrenomedullin production enhancer |
| KR101363311B1 (en) * | 2012-02-01 | 2014-02-17 | 공주대학교 산학협력단 | Zanthoxylum schinifolium extract for prevention and treatment of ulcerative colitis the composition comprising the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5486744B2 (en) | A composition for treating hepatitis, comprising extracts of muyuyo flowers, leaves of thorny banci and turmeric roots | |
| Rodahl | Hypervitaminosis A in the Rat Eighteen Figures | |
| RU2699011C2 (en) | Pharmaceutical composition containing silybin and l-carnitine | |
| WO2021249420A1 (en) | Use of kadsura heteroclita (roxb.) craib agent in preparation of medicament for resisting rheumatoid arthritis | |
| US8945633B2 (en) | Pharmaceutical composition for preventing and treating inflammatory diseases containing an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, and method for producing the fraction | |
| KR100699790B1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a Lonicera caerulea L. var. edulis extract | |
| TW201618801A (en) | Pharmaceutical composition used for assisting chemotherapy drug and application thereof | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| KR100786122B1 (en) | Composition effective for prevention and treatment of obesity which contains crude drug extract | |
| JP2002145791A (en) | Anti-inflammatory composition | |
| WO2006120974A1 (en) | Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage | |
| EP4248964A1 (en) | Pharmaceutical composition for treating sepsis, and use thereof | |
| CN114432342A (en) | Application of cell-free fat extract in treating ulcerative colitis | |
| JP4480204B2 (en) | Anti-tumor fraction of Kawariharatake | |
| JP4080350B2 (en) | Anti-arthritic food consisting of vitamin U and sulfur-containing yeast | |
| CN106511394B (en) | Application of aspongopus fatty oil extract | |
| EP2025340A1 (en) | Plant extracts for the treatment of rheumatoid arthritis | |
| Murthy et al. | Therapeutic properties of processed aqueous extract of Asteracantha longifolia in the human | |
| JPH06107553A (en) | Composition having analgesic function | |
| KR100352148B1 (en) | Compositions for angiogenesis and preventing and treating arthritis comprising β-sitosterol | |
| TWI745609B (en) | Composition for promoting antioxidative activity | |
| CN108938749B (en) | Pharmaceutical composition and preparation method and application thereof | |
| OMORODION et al. | POSSIBLE THERAPEUTIC EFFECTS OF Dioscorea alata (WATER YAM) EXTRACT ON TRAMADOL-TREATED WISTAR ALBINO RATS'GASTROINTESTINAL SYSTEM. | |
| JPH11180865A (en) | Mixture of lactic acid condensate and composition containing the same | |
| Hilton | Rate of the Enzymatic Breakdown of Digitoxin. |